LIVINGSTON, NJ / ACCESSWIRE / May 22, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today confirms that it regained compliance with the stockholder's equity requirements under the continued listing standards of the NYSE American LLC ("Exchange"). In November 2018, Milestone Scientific received notice from the Exchange that the Company was not then in compliance with the continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide. On December 20, 2018, the Company submitted a plan to achieve compliance (the "Plan") by May 20, 2020.

Anyone researching Milestone Scientific Inc. (NYSEMKT:MLSS) might want to consider the historical volatility of the...

Pressure waveform recording through the epidural catheter resulted in 100% sensitivity and specificity, as well as a positive predictive value of 100% LIVINGSTON, NJ / ACCESSWIRE / May 13, 2020 / Milestone ...

Reports positive feedback and growing interest in CathCheck™ LIVINSTON, NJ / ACCESSWIRE / May 18, 2020 / Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery ...

ROSELAND, NJ / ACCESSWIRE / April 14, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that on April 14, 2020 it closed its previously announced underwritten offering of 4,750,000 shares of its common stock and warrants to purchase up to an aggregate of 2,375,000 shares of the its common stock. Each share of common stock was sold together with a warrant to purchase 0.50 of one share of common stock at a combined price to the public of $0.95. In addition, Milestone Scientific granted to Maxim Group LLC a 45-day option to purchase up to an additional 712,500 shares of common stock and/or warrants to purchase up to 356,250 shares of common stock for the purposes of covering any over-allotments, at the public offering price less discounts and commissions, of which Maxim Group LLC partially exercised its option to purchase 200,000 shares of common stock and warrants to purchase up to 335,000 shares of common stock.

LIVINGSTON, NJ / ACCESSWIRE / April 15, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has validated the new "Quick Start," which has been implemented into the CompuFlo® Epidural System. The Quick Start feature simplifies and provides an alternative pathway to reduce the procedure preparation time for the CompuFlo® instrument prior to the procedure.

LIVINGSTON, NJ / ACCESSWIRE / March 30, 2020 / Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, ...

Milestone Scientific Inc. (NYSEMKT:MLSS) came out with its first-quarter results last week, and we wanted to see how...

Market forces rained on the parade of Milestone Scientific Inc. (NYSEMKT:MLSS) shareholders today, when the covering...

LIVINGSTON, NJ / ACCESSWIRE / May 22, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Red Chip will host an investor webinar and Q&A session with Leonard Osser, Interim Chief Executive Officer, to discuss the company's recent developments and upcoming milestones. Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.

As you might know, Milestone Scientific Inc. (NYSEMKT:MLSS) last week released its latest full-year, and things did...

ROSELAND, NJ / ACCESSWIRE / April 8, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today that it intends to offer for sale a combination of shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. Maxim Group LLC is acting as sole book-running manager for the offering. The securities described above are being offered by Milestone Scientific pursuant to a registration statement (File No. 333-231178) previously filed and declared effective by the Securities and Exchange Commission (SEC).

CompuFlo® reduced costs an average of $504 per hospital stay Study results presented for the 45th Annual Regional Anesthesiology and Acute Pain Medicine Meeting 2020 Poster presented by leading researcher ...

LIVINGSTON, NJ / ACCESSWIRE / May 13, 2020 / Milestone Scientific Inc. (NYSE:MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced ...

LIVINGSTON, NJ / ACCESSWIRE / April 21, 2020 / Milestone Scientific Inc. (MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has validated and integrated the new CathCheck™ feature into the CompuFlo® Epidural System. Using CathCheck™, physicians and nurses can monitor the placement of a catheter to determine the presence or absence of a pulsatile waveform (heartbeat) providing new information that can be used to determine if the catheter is in place or has become dislodged from the epidural space. This can be performed within seconds by measuring the pulsatile waveform within the epidural space.

LIVINGSTON, NJ / ACCESSWIRE / April 29, 2020 / Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, ...

LIVINGSTON, NJ / ACCESSWIRE / March 30, 2020 / Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, ...

Today is shaping up negative for Milestone Scientific Inc. (NYSEMKT:MLSS) shareholders, with the covering analyst...

LIVINGSTON, NJ / ACCESSWIRE / March 24, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it will be presenting at the 2020 Spring Investor Summit being held on March 25th-26th, featuring over 500 registered executives and investors. Due to the ongoing concerns related to COVID-19, the Spring Investor Summit, which was originally scheduled to take place in New York City, will now be hosted virtually. Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, is scheduled to present on Wednesday, March 25th at 11:20 a.m. Eastern Time.

ROSELAND, NJ / ACCESSWIRE / April 9, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, announced today the pricing of an underwritten offering of 4,750,000 shares of its common stock and warrants to purchase up to an aggregate of 2,375,000 shares of the its common stock. Each share of common stock is being sold together with a warrant to purchase 0.50 of one share of common stock at a combined price to the public of $0.95. The warrants will be immediately exercisable at a price of $1.20 per share of common stock and will expire three years from the date of issuance.